CAR T-cell Therapy Drug Pipeline Market 2022 Research Report: Overview of 300+ Companies and 300+ Drugs in Pipeline

DUBLIN, February 07, 2022–(BUSINESS WIRE)–The « CAR T Cell Therapy – Pipeline Overview, 2022 » clinical trials have been added to from offer.

This report provides comprehensive information on over 300 companies and over 300 drugs under development in the CAR T-cell therapy pipeline landscape.

It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

Report Highlights

Companies and academics are working to assess challenges and seek out opportunities that may influence research and development of CAR T-cell therapy. Therapies being developed focus on new approaches to treat/enhance CAR T-cell therapy.

CAR T-cell Therapy Emerging Drug Chapters

This segment of the CAR T-cell Therapy report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Emerging drugs for CAR T-cell therapy

JWCAR029: JW Therapeutic

JWCAR029 is a CD19-targeting CAR-T cell product for the treatment of late-stage lymphomas and leukemias (second-line therapy or higher). The molecule is in phase II development. Initially, JWCAR029 is being investigated for the treatment of B-cell malignancies focusing on relapsed and refractory DCBCL. In June 2020, the National Medical Products Administration (“NMPA”) accepted for review its NDA for relma-cel as a third-line treatment for DLBCL. The drug is currently in the pre-registration phase for the treatment of diffuse large B-cell lymphoma.

Descartes-11: Cartesian therapy

Descartes-011 are autologous CD8+ T cells expressing a chimeric anti-BCMA antigen receptor. Descartes-11 is currently in phase II clinical trials to treat patients with multiple myeloma on an outpatient basis.

CNCT19: CASI Pharmaceutical

CNCT19 is developed by CASI Pharmaceuticals in collaboration with Juventas Cell Therapy. CNCT19 is currently in phase II for non-Hodgkin lymphoma, relapsed or refractory acute lymphoblastic leukemia and in phase I/II for large B-cell lymphoma.

CTL119: Novartis

CTL119 (CD19 CAR) is a humanized CD19 CAR being developed by Novartis in collaboration with the University of Pennsylvania and is currently in Phase II for the treatment of acute lymphocytic leukemia. CTL119 is produced with a patient’s T cells, some of which are removed and then reprogrammed in Penn’s clinical cell and vaccine production facility with a gene transfer technique designed to demonstrate that T cells target and kill tumor cells.

The modified cells contain an antibody-like protein known as CAR, which is designed to bind to the CD19 protein on the surface of cancerous B cells. The modified “hunter” cells are then injected back into the patient’s body, where they multiply and are supposed to attack the cancer cells.

P-BCMA-101: Poseida Therapeutic

P-BCMA-101 is the company’s lead investigational CAR-T immunotherapy, designed to supercharge a patient’s T cells to safely and effectively kill tumor cells that carry the B-cell maturation antigen ( BCMA), which is expressed on virtually all multiple myeloma cells. It modifies a patient’s T cells using the superimposed Transposon system, which enables several desirable features.

It is a next-generation CAR T-cell therapy designed to maintain highly potent and long-lasting activity against BCMA, an antigenic target expressed on virtually all multiple myeloma cells. P-BCMA-101 encodes a CARTyrine that targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM) and has several unique aspects that improve upon earlier CAR T products. It is currently in phase 2 development for the treatment of multiple myeloma.

AUTO4: Autolus Limited

AUTO4 is a T cell programmed therapy product candidate developed by Autolus Limited to take advantage of a novel targeting approach based on the mutually exclusive expression of two T cell receptor beta chain subtypes: AUTO4 targets TRBC1 , while the company’s other product candidate in development, AUTO5, targets TRBC2. Normal T cells contain both TRBC1 and TRBC2 compartments, while T-cell lymphoma cells are derived from mature cells and express only TRBC1 or TRBC2. The therapeutic candidate is in phase I/II development for the treatment of patients with relapsed or refractory TRBC1-positive selected PTCL.

Descartes-08: Cartesian therapy

Descartes-08 is an investigational CD8+ CAR-T therapy that targets cells expressing B-cell maturation antigen (BCMA), a protein expressed by all plasma cells. Descartes-08 is designed to have a defined and predictable half-life, allowing for repeated dosing to maximize potency while minimizing the risk of toxicity. Descartes-08’s enhanced safety features allow use for a wide range of diseases, from multiple myeloma and other cancers to autoimmune diseases. Descartes-08 is currently in Phase I/II clinical trials to treat patients with multiple myeloma on an outpatient basis.

ET140202: Eureka Therapeutic

Eureka Therapeutics is developing ET140202 (also known as ET1402; ET1402L1), an investigational CAR T therapy for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. The therapeutic candidate is a humanized antibody, identified from Eureka’s proprietary ALPHA phage library, that selectively targets liver cancer cells overexpressing alpha-fetoprotein (AFP). ET1402 is selective and specific for the peptide AFP158-166 complexed with human leukocyte antigen (HLA)-A*02:01. The Company, in collaboration with the City of Hope, is evaluating ET1402 in Phase I/II development for the treatment of liver cancer.

MB-102: Organic Mustang

Mustang Bio (a subsidiary of Fortress Biotech) is developing MB-102 which is a CAR T-cell therapy that contains an scFv antibody targeting the CD123 antigen with a CD28 co-stimulatory domain and an essential activation domain CD3? as well as the extracellular domain of EGFR (EGFRt) as a selection/safety marker. It is in Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML).

AU101: Aurora Biopharma

AU101 is under development by Aurora Biopharma. It is a chimeric CAR T-cell therapy that contains a HER2-targeting scFv antibody with a CD28 costimulatory domain and an essential CD3 activator domain, transfected into autologous CMV-pp65 T cells using a retroviral virus. The therapeutic candidate is in phase I/IIa development for the treatment of Recurrent Glioblastoma; Sarcoma/Osteosarcoma. The CAR T-cell therapeutic agent targets the expression of HER2. Preclinical studies in animals with different cancers have shown that AU101 kills tumors in various cancers in about two weeks. Aurora has a clinical trial collaboration to conduct CAR T trials with Baylor College of Medicine, Texas Children’s Hospital and Baptist Methodist Hospital in Houston, TX.

CAR T-cell Therapy: Therapeutic Assessment

This segment of the report provides information about the different CAR T-cell Therapy drugs separated based on the following parameters which define the scope of the report.

CAR T Cell Therapy: Pipeline Development Activities

The report provides an overview of different therapeutic candidates in phase II, I, preclinical and discovery. It also analyzes the key CAR T-cell Therapy Therapeutic Drug players involved in the development of key drugs.

Pipeline development activities

The report covers the detailed information on collaborations, acquisition and merger, licensing as well as an in-depth therapeutic evaluation of emerging CAR T-cell therapy drugs.

Key players

  • Sorrento Therapy

  • Cartesian therapy

  • CASI Pharmaceutical

  • Novartis

  • Therapeutic Poseida

  • Shanghai Unicar-Therapy Bio-medicine Technology

  • Sinobioway Cell Therapy Co., Ltd.

  • Gilead Sciences

  • Therapeutic Tessa

  • Wuhan Biotechnology Bio-Raid

  • Autolus Limited

  • Beijing Immunochina Medical Science and Technology

  • BioAtla

  • BioInvent International

  • Carsgen Therapeutic

  • Chongqing Precision Biotechnology

  • Therapeutic Eureka

  • Formula Pharmaceuticals

  • Guangzhou Bio-Gen Technology

  • Hebei Senlang Biotechnology

  • Organic Mustang

  • MolMed

  • Aurora BioPharma

  • Atara Biotherapeutics

  • Bellicum Pharmaceuticals

  • Kecellitics Biotech Company Ltd

  • Yake Biotechnology

  • Minerva Biotechnology

  • Shanghai GeneChem Co., Ltd.

  • Allogeneic therapy

  • Miltenyi Biotec

  • PersonGen BioTherapeutics (Suzhou)

  • Precision Biosciences

  • Takara Organic

  • BioNTech

  • Miltenyi Biomedicine

  • CRISPR therapeutics

  • Celgene

  • Cellectis

  • Céliade

  • Organic Gracell

  • servant

  • Protheragen

  • Noile-Immune Biotech

  • Arcellx Inc.

  • HRAIN Biotechnology

  • Tmunity Therapeutics Inc.

  • AffyImmune Therapeutics

  • Maxcyte

  • Therapeutic Kuur

  • TILT Biotherapeutic

  • Targazyme

  • TC BioPharm

  • Takeda

  • Sensei Biotherapeutics

  • Sana Biotechnology

  • Eternal Therapy

  • Humorigin

  • fate therapy

  • Enlivex Therapeutics Ltd

  • exuma

  • Caribou Biosciences

  • Arbele Limited

  • Organic Adicet

Key products


  • Descartes-11

  • CNCT19

  • CTL119

  • P-BCMA-101

  • EPCAM-targeted CAR-T cells

  • KTE-X19

  • TT11

  • AUTO4

  • AUTO3

  • IM19 CAR-T



  • CSG-CD19

  • CT053

  • Descartes-08

  • PCAR-19B

  • BCMA CAR-T cells

  • ET140202

  • CIK-CAR.CD19

  • BG-T19

  • Autologous CAR T cells targeting CD19 (Senl-001)

  • MB-102

  • CAR-T CD44v6 autologous cell therapy

  • AU101

  • ATA2271

  • AUTO1

  • BPX-601

  • CD123 CAR T cell therapy

  • CAR anti-CD22

  • huMNC2-CAR44 CAR T cells

  • ALLO-501A

  • AUTO1/22

  • ET 1402L1-CART

  • BPX-603

  • MB CART 20.1

  • MB-106

  • PCAR-019

  • Anti-MUC1 CAR-T cells

  • PBCAR0191

  • PBCAR269A

  • TBI-1501

  • BNT211

  • MB-CART19.1

  • iCarTAB BioMed

  • CTX101

  • Bluebird Organic

  • bb21217

  • JCAR 018

  • UCART123

  • CYAD-02

  • GC027

  • BIN-102

  • TMUN ONC 001

  • AIC100

  • MCY-M11

  • KUR-501

  • TILT-T392

  • TZ-102

For more information on this clinical trial report, visit

See the source version on

Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Back To Top